These statements may be identified by thefact that they use words such as “anticipate”, “estimates”, “should”, “expect”,”guidance”, “project”, “intend”, “plan”, “believe” and other words and terms ofsimilar meaning in connection with any discussion of future operating orfinancial performance. Such forward-looking statements are based on currentexpectations and involve inherent risks and uncertainties, including factorsthat could delay, divert or change any of them, and could cause actual outcomesand results to differ materially from current expectations. Thesefactors also include the company`s ability to execute successfully its strategicplans, including its Productivity Transformation Initiative, the expiration ofpatents or data protection on certain products (including the expiration of dataprotection for PLAVIX in the European Union), and the impact and result ofgovernmental investigations. There can be no guarantees with respect to pipelineproducts that future clinical studies will support the data described in thisrelease, that the products will receive necessary regulatory approvals, or thatthey will prove to be commercially successful; nor are there guarantees thatregulatory approvals will be sought, or sought within currently expectedtimeframes, or that contractual milestones will be achieved. For further detailsand a discussion of these and other risks and uncertainties, see the company’speriodic reports, including the annual report on Form 10-K, quarterly reports onForm 10-Q and current reports on Form 8-K, filed with or furnished to theSecurities and Exchange Commission. The company undertakes no obligation topublicly update any forward-looking statement, whether as a result of newinformation, future events or otherwise.
Company and Conference Call InformationBristol-Myers Squibb is a global biopharmaceutical company whose mission is toextend and enhance human life There will be a conference call on April 28, 2009 at 11 a.m. (ET) during whichcompany executives will address inquiries from investors and analysts. Investorsand the general public are invited to listen to a live web cast of the call at or by dialing 913-312-1270, confirmation code 6583248.Materials related to the call will be available at the same website prior to thecall. For more information, contact: Brian Henry, 609-252-3337, Communications, TracyFurey, 609-252-3208, Communications, John Elicker, 609-252-4611, InvestorRelations, or Suketu Desai, 609-252-5796, Investor Relations ABILIFY® is the trademark of Otsuka Pharmaceutical Co., Ltd ATRIPLA is a trademark of both Bristol-Myers Squibb Co and Gilead Sciences,Inc. AVAPRO®, AVALIDE® and PLAVIX® are trademarks of sanofi-aventis ERBITUX® is a trademark of ImClone LLC. ImClone Systems is a wholly-ownedsubsidiary of Eli Lilly and Company. BRISTOL-MYERS SQUIBB COMPANYNET SALES BY OPERATING SEGMENTSFOR THE THREE MONTHS ENDED MARCH 31, 2009 AND 2008 (Unaudited, dollars in millions) Three Months Ended March 31 20092008BioPharmaceuticals$ 4,322$ 4,188Mead Johnson693703Net Sales $ 5,015$ 4,891BRISTOL-MYERS SQUIBB COMPANY SELECTED PRODUCTS FOR THE THREE MONTHS ENDED MARCH 31, 2009 AND 2008 (Unaudited, dollars in millions) The following table sets forth worldwide and U.S.
reported net sales forselected products for the three months ended March 31, 2009 compared to thethree months ended March 31, 2008. In addition, the table includes, whereapplicable, the estimated total U.S. prescription change for the retail andmail-order channels for the comparative periods presented for certain of thecompany’s U.S pharmaceutical products based on third-party data A significantportion of the company’s U.S pharmaceutical sales is made to wholesalers. Wherechanges in reported net sales differ from prescription growth, this change innet sales may not reflect underlying prescriber demand Worldwide Net Sales U.S Net Sales 20092008 %20092008%% Change in U.S Total Change Change Prescriptions vs.
BRISTOL-MYERS SQUIBB COMPANY NET DEBT CALCULATIONAS OF MARCH 31, 2009 AND DECEMBER 31, 2008(Unaudited, dollars in millions) March 31, 2009December 31, 2008Cash and cash equivalents$7,832$ 7,976Marketable securities-current 1,088289Short-term borrowings (156)(154)Long-term debt(6,492)(6,585)Net cash $2,272$ 1,526 Bristol-Myers Squibb CompanyCommunicationsBrian Henry, 609-252-3337Tracy Furey, 609-252-3208ORInvestor RelationsJohn Elicker, 609-252-4611Suketu Desai, 609-252-5796 Copyright Business Wire 2009. Aaron Schobel’s and Chris Kelsay’s contracts are huge, so are expectations. Last year, the two defensive ends had to play nearly every down with Al Wallace going down in the preseason, Ryan Denny’s foot injury, and Anthony Hargrove’s suspension. The Bills are looking at some free agents to lighten the load that Schobel and Kelsay will carry in 2008.St. Louis Rams’ defensive end James Hall is one of the top options for a Bills team looking to bolster its defensive line. The 31-year-old still has very unique pass rushing skills and could push Kelsay into becoming a better player. Most likely if signed, he would serve as a rotational player with the two incumbent defensive ends.I think the recently released Kalimba Edwards from Detroit should be looked at, as well.
The kid is a pretty goodfinesse rusher who would also serve as a great rotational player/backup.The Bills also might look to the draft for young depth at the DE position.. MIAMI–(Business Wire)–World Fuel Services Corporation (NYSE:INT) invites you to participate in aconference call with its management team on Thursday, May 7, 2009 at 5:00PMEastern Time to discuss the Company`s first quarter results, which it plans torelease after the close of the market on the same date. The live conference call will be accessible by telephone at (888) 354-3257(within the United States and Canada) or (706) 643-3925 (International). Audioreplay of the call will be available through May 21, 2009. The replay numbersare: (800) 642-1687 (within the United States and Canada) and (706) 645-9291(International) The call ID is 96242024.